1299P PD-1 blockade plus chemotherapy followed by concurrent hypofractionated radiotherapy with simultaneous integrated boost as induction therapy for patients with borderline resectable and locally advanced pancreatic cancer: A phase II clinical trial

Abstract

Pancreatic cancer is a kind of lethal malignant tumors with poor sensitivity to chemoradiotherapy and low resection rate. This study is to evaluate the safety and efficacy of anti-PD-1 inhibitor plus nab-paclitaxel and gemcitabine chemotherapy (AG) followed by concurrent hypofractionated radiotherapy with simultaneous integrated boost (SIB) as induction therapy for patients with borderline resectable (BRPC) and locally advanced pancreatic cancer (LAPC).